Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
441-460 of 3,900 trials

Colorectal Cancer: Flu Vaccine and Pembrolizumab Study

We are exploring whether a flu vaccine combined with pembrolizumab can help shrink tumors in patients with early pMMR colorectal cancer. The study will also assess safety and immune responses.

Colorectal Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Pleural Mesothelioma: Volrustomig with Carboplatin and Pemetrexed

We are studying a new treatment combination for patients with unresectable pleural mesothelioma. The goal is to see if it works better than current standard care options.

Unresectable Pleural Mesothelioma>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Ureter Visualization: Nizaracianine Triflutate in Surgery

We are studying a new intravenous drug to help surgeons see the ureters more clearly during abdominopelvic surgeries. This may improve safety and reduce the need for invasive procedures.

Urinary Tract ImagingEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesOtolaryngologyUrology

Tenosynovial Giant Cell Tumor: Study of ABSK021

We are investigating a new treatment, ABSK021, for patients with Tenosynovial Giant Cell Tumor to see if it is safe and effective compared to a placebo. The study will also assess how it affects tumor size and patient mobility.

Tenosynovial Giant Cell Tumor6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Endometrial Cancer: RAINBO Treatment Study

We are exploring a new treatment approach for patients with endometrial cancer based on their molecular features. The goal is to see if this can improve survival rates and reduce the chance of cancer returning.

Mismatch Repair Deficient High-Risk Endometrial Cancer>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesGynecology and ObstetricsOncology

Mitapivat for Erythrocyte Membranopathies

We are studying the safety and effects of mitapivat in adults with erythrocyte membranopathies. This includes looking at hemoglobin levels and how it may help with symptoms.

Erythrocyte Membranopathies>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteHematology

Postpartum Anemia: IV vs. Oral Iron Treatment

We are studying whether intravenous iron is more effective than oral iron in reducing postpartum depression and improving anemia in women after cesarean delivery. This trial will help us understand the best treatment options for new mothers facing these challenges.

Postpartum Depression with Iron Deficiency Anemia>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesGynecology and ObstetricsPsychiatry

Melanoma Treatment: ABP 206 vs. OPDIVO

We are evaluating a new treatment, ABP 206, for patients with advanced melanoma who have not been treated before. The study aims to see how well it works and how safe it is compared to OPDIVO.

Metastatic Melanoma>2 yearsConfirmation phase (III)>20 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncology

Bronchiectasis: Long-Term Study of BI 1291583

We are testing the long-term safety of BI 1291583 in people with bronchiectasis who have taken part in earlier studies. The study will also look at whether this treatment helps reduce lung flare-ups.

Bronchiectasis>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemotePulmonology

Osteogenesis Imperfecta: Romosozumab vs. Bisphosphonates

We are studying whether romosozumab can reduce fractures and improve bone density in children and adolescents with osteogenesis imperfecta compared to bisphosphonates. This trial will help us understand the safety and effectiveness of this new treatment.

Brittle Bone Disease1-2 yearsConfirmation phase (III)16-20 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOrthopedics and TraumatologyPediatrics

Biliary Tract Cancer: GAP Chemotherapy Study

We are studying whether a combination of chemotherapy before surgery helps patients with biliary tract cancers live longer and have better outcomes than those who undergo surgery right away.

Biliary Tract CancerEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesOncology

Malignant Pleural Effusion: Pressurized Aerosol Chemotherapy

We are testing a new method of delivering chemotherapy directly into the chest for patients with malignant pleural effusion. This study aims to evaluate how well this treatment works and its safety.

Malignant Pleural Effusion>2 yearsSafety phase (I)OncologyPulmonology

Metastatic Non-Small Cell Lung Cancer: Volrustomig Plus Chemotherapy

We are studying whether the new drug volrustomig combined with chemotherapy is more effective than pembrolizumab plus chemotherapy for patients with metastatic non-small cell lung cancer. This trial focuses on those with low PD-L1 levels.

Metastatic Non-Small Cell Lung Cancer≤3 monthsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Daridorexant for Insomnia in Alzheimer's Patients

We are studying whether daridorexant can improve sleep quality in individuals with mild cognitive impairment and mild to moderate Alzheimer's disease. This trial aims to evaluate its effects on sleep duration, daytime functioning, and overall health.

Insomnia Disorder>2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementNeurologyPsychiatry

Hearing Loss Prevention: Sodium Thiosulfate for Chemotherapy Patients

We are studying whether transtympanic sodium thiosulfate can help prevent hearing loss in patients receiving cisplatin chemotherapy. This trial will compare its effects on hearing with those of untreated ears.

Head and Neck Cancer3-6 monthsConfirmation phase (III)No PlaceboStandard MedicinesOncologyOtolaryngology

Tislelizumab for Cancer Patients with Residual Disease

We are studying whether tislelizumab can help cancer patients who still have detectable disease after standard treatment. The goal is to see if it improves their chances of staying cancer-free compared to a placebo.

Pancreatic CancerSoft Tissue SarcomaNon-Small Cell Lung Cancer>2 yearsConfirmation phase (III)16-20 visitsStandard MedicinesPartially RemoteGastroenterologyOncologyPulmonology

Metastatic Renal Cell Carcinoma: Treatment Comparison Study

We are comparing two treatment combinations for patients with metastatic renal cell carcinoma to see which one improves survival and quality of life. This study is for those who have not received treatment before and have specific risk factors.

Metastatic Renal Cell CarcinomaConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesInternal MedicineOncology

Ewing Sarcoma: Regorafenib with Chemotherapy

We are studying a new combination of regorafenib and standard chemotherapy for patients with newly diagnosed multimetastatic Ewing sarcoma. The goal is to find the best dose and evaluate its safety and effectiveness.

Metastatic Ewing Sarcoma>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesOncologyOrthopedics and Traumatology

Oligometastatic Non-Small Cell Lung Cancer: Immunotherapy with Local Treatments

We are studying whether adding a local treatment to standard immunotherapy helps improve survival for patients with oligometastatic non-small cell lung cancer. This trial will also look at quality of life and side effects.

Synchronous Oligometastatic Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesOncologyPulmonology

Sjögren’s Syndrome: Deucravacitinib Study

We are testing a new medication, deucravacitinib, for adults with active Sjögren’s Syndrome to see if it improves symptoms better than a placebo. The study also looks at the safety and tolerability of this treatment.

Sjogren's Syndrome1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementRheumatology